Key facts
- It has raised $440K across 1 recorded rounds; the latest was Seed Round in Aug 2025.
- Notable investors include Golden Angels Investors, BrightStar Wisconsin Foundation, Charlottesville Angel Network.
- Tundra Targeted Therapeutics has filed 1 Form D with the SEC, most recently Jun 2025 ($444K sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tundra Targeted Therapeutics
Funding rounds
1 roundsAbout Tundra Targeted Therapeutics
Developer of bispecific antibodies designed to improve cancer treatment. The company offers antibodies that bring a patient's own T cells into contact with specific antigens on tumor cells, providing targeted cancer cell killing with fewer side effects than current approaches, without the costs and risks of genetic engineering, enabling customers to have improved affordability for cancer treatments.
- Sector
- Healthcare
- HQ
- Milwaukee, WI, United States
- Founded
- 2021
- Ownership
- Privately Held (backing)
Tundra Targeted Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tundra Targeted Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tundra Targeted Therapeutics in its N-PORT filings yet. We sweep new filings monthly.